Susanne Hedbom

583 total citations
5 papers, 463 citations indexed

About

Susanne Hedbom is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, Susanne Hedbom has authored 5 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Cell Biology. Recurrent topics in Susanne Hedbom's work include Cancer-related Molecular Pathways (2 papers), Cancer Research and Treatments (2 papers) and Microtubule and mitosis dynamics (2 papers). Susanne Hedbom is often cited by papers focused on Cancer-related Molecular Pathways (2 papers), Cancer Research and Treatments (2 papers) and Microtubule and mitosis dynamics (2 papers). Susanne Hedbom collaborates with scholars based in Germany and India. Susanne Hedbom's co-authors include Annette Frost, Simone Steinbild, K. Mross, Clemens Unger, Martin Büchert, Roland Heinig, Jörn Krätzschmar, Oliver Boix, Ulrike Fasol and Olaf Christensen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Current Oncology.

In The Last Decade

Susanne Hedbom

5 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susanne Hedbom Germany	4	277	167	120	119	82	5	463
Edith Rodríguez-Braun Spain	11	331 1.2×	157 0.9×	154 1.3×	105 0.9×	63 0.8×	21	478
S. Curley United States	8	274 1.0×	287 1.7×	134 1.1×	50 0.4×	46 0.6×	12	606
Christopher Riley United States	8	177 0.6×	179 1.1×	117 1.0×	26 0.2×	18 0.2×	11	514
Young Bae Kim South Korea	14	222 0.8×	347 2.1×	154 1.3×	28 0.2×	169 2.1×	27	848
Muaiad Kittaneh United States	16	447 1.6×	294 1.8×	312 2.6×	21 0.2×	55 0.7×	40	739
Jun Ji China	15	202 0.7×	285 1.7×	70 0.6×	21 0.2×	174 2.1×	29	673
Herb Kotz United States	11	325 1.2×	148 0.9×	130 1.1×	82 0.7×	16 0.2×	23	494
Rita Ruijter Netherlands	11	332 1.2×	212 1.3×	92 0.8×	17 0.1×	23 0.3×	14	841
R. Molife United Kingdom	11	291 1.1×	300 1.8×	277 2.3×	70 0.6×	10 0.1×	24	694
A. D. Colevas United States	10	391 1.4×	355 2.1×	113 0.9×	64 0.5×	17 0.2×	24	652

Countries citing papers authored by Susanne Hedbom

Since Specialization

Citations

This map shows the geographic impact of Susanne Hedbom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanne Hedbom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanne Hedbom more than expected).

Fields of papers citing papers by Susanne Hedbom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanne Hedbom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanne Hedbom. The network helps show where Susanne Hedbom may publish in the future.

Co-authorship network of co-authors of Susanne Hedbom

This figure shows the co-authorship network connecting the top 25 collaborators of Susanne Hedbom. A scholar is included among the top collaborators of Susanne Hedbom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanne Hedbom. Susanne Hedbom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Mross, K., Annette Frost, Simone Steinbild, et al.. (2012). A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(9). 2658–2667. 262 indexed citations

2.

Frost, Annette, K. Mross, Simone Steinbild, et al.. (2012). Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology. 19(1). 28–35. 62 indexed citations

3.

Mross, K., Annette Frost, Simone Steinbild, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(34). 5511–5517. 129 indexed citations

4.

Hedbom, Susanne, Simone Steinbild, Annette Frost, et al.. (2007). Phase I study of BAY 73–4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3593–3593. 7 indexed citations

5.

Strumberg, Dirk, M. E. Scheulen, Annette Frost, et al.. (2006). Phase I study of BAY 57–9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3089–3089. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact